5 completed, 2 active not recruiting, 2 terminated. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Active not recruiting 2, Terminated 2 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow entrectinib: new trials by email Literature Review of entrectinib trials Research Report on entrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Decitabine and Cedazuridine, Entrectinib, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 13 | 2022-10-28 | 2026-10-15 |
| Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma PAC-1, Entrectinib - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Arkadiusz Z. Dudek, MD | 6 | 2021-01-11 | 2023-11-22 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function entrectinib - Hepatic Insufficiency | Phase 1 | Completed | Hoffmann-La Roche | 38 | 2020-02-11 | 2024-08-02 |
| A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers. Entrectinib 600 mg (T1), Entrectinib 600 mg (T2), Entrectinib 200 mg (R) - Solid Tumor | Phase 1 | Completed | Genentech, Inc. | 31 | 2019-06-06 | 2020-09-07 |
| Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients Entrectinib, Midazolam Hydrochloride - Advanced Solid Tumor | Phase 1 | Completed | Hoffmann-La Roche | 15 | 2017-11-14 | 2018-08-21 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Entrectinib - Solid Tumors, CNS Tumors | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 69 | 2016-05-03 | 2026-09-23 |
| Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Entrectinib - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Hoffmann-La Roche | 84 | 2014-07-28 | 2021-06-09 |
Leukemia, Myeloid, Acute (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Anemia (1) · Blast Crisis (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Hepatic Insufficiency (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1)
Hoffmann-La Roche (4) · OHSU Knight Cancer Institute (2) · Arkadiusz Z. Dudek, MD (1) · Genentech, Inc. (1) · Presage Biosciences (1)
United States (7) · United Kingdom (2) · Canada (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Slovakia (1) · South Korea (1) · Spain (1)
Arkadiusz Dudek, MD, PhD (1) · Gary Deutsch, MD (1) · Kenneth Gundle, MD (1) · Lara Davis, MD (1) · Ronan T Swords, M.D. (1) · Seth Pollack, MD (1)
PMID 31838007, PMID 26565381, PMID 26884591, PMID 31838015, PMID 32299817, PMID 33646820, PMID 34427452, PMID 35395680, PMID 37738028, PMID 39549678, PMID 39863139, PMID 39934586, PMID 40086048
2019 (2), 2023 (1)